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Ab s t r a c t
Introduction: Thrombosis (VTh) is a rare dangerous complication of pacemaker
implantation (PM). The aim of the study was to determine the dynamics of
change in selected thrombotic and inflammatory factors after PM.
Material and methods: The study involved 81 patients (30 female, mean age:
71.1 years) with PM, divided into two groups. Group A (71 patients) consisted of
patients without VTh, whereas group B (10 patients) comprised the patients
with VTh. A transthoracic echocardiogram (TTE) and a venous ultrasound (VU)
examination were performed. The levels of D-dimers, fibrinogen, tissue factor
(TF), factor VII, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6) and
high-sensitivity C-reactive protein (hsCRP) were determined in the venous blood.
After PM, the TTE and VU examinations were repeated at 6 and 12 months, and
blood analyses were performed within 7 days after PM, and subsequently at 
6 and 12 months.
Results: In 10 patients of group B, symptomatic VTh occurred at a mean time
of 13.06 months after PM. Initially, the levels of IL-6, hsCRP, D-dimers, fibrinogen,
TF, VII factor and PAI-1 were considerably higher in group B than in group A. 
In all patients the levels of these factors kept on increasing for up to 7 days after
the procedure. In group A they subsequently decreased, whereas in group B they
continued to rise. 
Conclusions: Increased levels of inflammatory and thrombotic factors were
observed in patients with VTh before and after PM. The factors of highest risk
of VTh occurrence were D-dimers, fibrinogen and TF.
Key words: venous thrombosis, cardiac pacing, inflammatory and thrombotic factors.
Introduction
Major complications of pacemaker implantation include venous occlu-
sion [1], thrombus formation in cardiac cavity [2, 3], superior vena cava
syndrome [4, 5], recurrent venous thrombotic events and post-thrombo -
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tic syndrome [6]. Symptoms of thrombosis occur in
about 0.5-5% and life-threatening blood clots in
0.6-3.5% of all pacemaker implantation cases [6].
Approximately 30-50% of the patients develop
phlebitis as a complication of transvenous lead
placement. It is most frequently subclavian, brachial
or axillary phlebitis [6].
Rozmus et al. [7] performed a meta-analysis 
(a total of 711 patients) of venous thrombosis (VT)
in patients after pacemaker implantation (PM).
Abnormal venography results were found in 38%
of the patients, venous occlusion in 11%, and symp-
tomatic VT in only 2.6% of the patients.
Subclavian or brachiocephalic vein occlusion is
a complication that develops in 8-21% of the pa -
tients, whereas superior vena cava occlusion lead-
ing to superior vena cava syndrome develops in
0.03-0.4% [8].
Studies of VT as a complication of pacemaker im -
plantation have shown ambiguous results. A num-
ber of risk factors for the development of this com-
plication have been identified [1, 6, 7]. The present
study is an attempt to explain the dynamics of
change in selected hemodynamic and biochemical
parameters (prothrombotic and proinflammatory
markers) predisposing to the development of throm-
botic events after the implantation of a pacemaker.
Material and methods
The study group comprised 81 patients (30 fe -
males, 51 males, mean age: 71.1 ±7.4 years) with 
a cardiac pacemaker. Patients were divided accor -
ding to the absence or presence of VT in the post-
implantation period into group A (28 females, 
43 males; mean age: 71.2 ±7.6 years) and group B
(2 females, 8 males; mean age: 72.6 ±7.2 years),
respectively.
The exclusion criteria were: (1) lack of informed
consent, (2) upper extremity venous stenosis before
implantation, (3) inability to obtain diagnostic ima -
ges, (4) artificial valves, status after percutaneous
coronary interventions, patients qualified for pace-
maker upgrade, and chronic anticoagulation and
anti-aggregation therapy. 
All patients were subsequently followed up for
18 months. During follow-up 29 patients were
excluded at 7 days and 3 more at 6 months from
group A after initiation of anticoagulation treat-
ment; therefore 42 patients and 39 patients were
available for analysis at 6 and 12 months, respec-
tively. Three patients from group B, who developed
thrombosis, were excluded at 6 months; therefore
7 patients were re-examined at 12 months. In the
remaining subjects thrombotic events occurred at
a later time. Both groups were comparable with
respect to age and gender.
Thirty-two patients received anticoagulation
therapy (acenocoumarol), 31 diuretics, 49 anti-
hypertensive medications (ACE-I, β-blockers), 30 sta -
tins and 24 digoxin during the observation period.
Twenty-seven patients had a history of myocardial
infarction, 4 of cerebral stroke, 31 were diagnosed
with heart failure, 30 with atherosclerosis and 
49 with arterial hypertension. 
Transthoracic echocardiography (TTE) was per-
formed with a Prosound α 10, Aloka echo machine.
Left ventricular ejection fraction (LVEF) was calcu-
lated using Simpson’s method in the apical four-
and two-chamber view. Left ventricular diastolic
function was evaluated based on early flow prop-
a gation velocity (Vp) by color M-mode Doppler in the
apical four-chamber view. Left ventricular end-dias-
tolic diameter (LVEDD) was measured in parasternal
long-axis view in the basal segments using M-mode
echocardiography. 
Upper extremity ultrasound (VU) was performed
using a Vivid 7 Expert device and linear probe 
5-13 MHz to assess venous systems of the left and
right upper limb, shoulder girdle and neck. The mor-
phology and flow were assessed using a duplex
pulsed-Doppler/real-time system. Heart and vas-
cular examinations (TTE, VU) were performed
before and at 6 and 12 months after PM.
Blood was drawn from the antecubital vein at 
7 o’clock after obtaining individual written informed
consent. Citrated plasma and sera were stored at
–70°C until assay. In citrated plasma samples we
determined D-dimer concentrations by use of an
immunoturbidimetric method, fibrinogen levels
using a coagulometric method, plasminogen acti-
vator inhibitor-1 (PAI-1) and tissue factor (TF) by
immunoenzymatic assay, and factor VII activity
based on the prothrombin time. In blood serum we
measured high-sensitivity C-reactive protein (hsCRP)
using nephelometric methods and IL-6 by immu-
noenzymatic assay.
Blood tests were performed before and after
pacemaker implantation (on day 7 and at 6 and 
12 months).
Statistical analysis
Descriptive statistics (arithmetic mean (x), stan-
dard deviation (SD), median (Me), minimum (min)
and maximum (max) value, number of patients (n))
were used to describe hemodynamic and biochemi -
cal parameters.
Unpaired Student’s t-test or Mann-Whitney 
U test was used to test for differences between
groups. Paired Student’s t-test or Wilcoxon test was
used to test for differences between measure-
ments. The rate of change between study groups
was calculated from differences between the con-
secutive measurements (deducting the value from
the preceding one) for each variable in each patient.
Receiver operating characteristic curve (ROC) analy-
sis was used to determine the diagnostic strength
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of the hemodynamic and biochemical parameters
in predicting the risk of thrombosis. The cut-off point
was calculated for each parameter based on You -
den’s index.
Logistic regression analysis was used to calcu-
late odds ratio (OR) and 95% confidence interval
and define the impact of specific parameters on the
risk of thrombosis.
A p value ≤ 0.05 was considered as statistically
significant. Calculations were performed using the
Statistica 9.0 and MedCalc packages.
The present study was approved by the Jagiel-
lonian University Bioethics Committee (approval
no. KBET/63/B/2009).
Results
The two groups did not differ with respect to the
pacing mode. Patients in group B had a significantly
lower left ventricular ejection fraction, larger dias-
to lic dimensions and impaired inflow as compared
with group A. During the 18-month follow-up period
the ejection fraction and the early flow Vp increa sed,
whereas the diastolic di men sion decreased (Table I,
Figure 1).
The symptoms of VT occurred in 10 patients in
group B at a mean of 13.06 months (7-17 months),
i.e. in 12.3% of the whole study population. The sub-
clavian and brachiocephalic veins on the side of PM
were occluded.
Initially plasma levels of prothrombotic (D-di mers,
fibrinogen, TF, VII, PAI-1) and proinflammatory (IL-6,
hsCRP) markers were markedly higher in group B
than in group A. In all study patients the values con-
tinued to rise until the 7th day after PM. At 6 and 
12 months after the procedure the trend towards
increasing plasma levels of these markers was
observed only in group B. In group A the levels
returned to normal (Table II, Figures 2 and 3). The
cut-off values for hemodynamic parameters and
biochemical markers that confer increased risk of
VT (p < 0.001) were calculated using ROC curve analy-
sis (Table III). The univariate analysis (Table IV) and
ROC curve analysis identified D-dimers, fibrinogen
and TF as the risk factors for thrombotic events.
The small sample size did not allow for multiva -
riate analysis of our data.
Discussion
In this paper we discuss the dynamics of
changes in selected echocardiographic parameters,
inflammatory molecules and thrombotic factors, in
patients before pacemaker implantation and after
the operation, that correlate with the risk of venous
thrombosis. The number of the patients, especially
in group B (with vein thrombosis) is very limited,
which may slightly affect the accuracy of our find-
ings. Nevertheless, despite the small sample size,
this study is of clinical importance as its findings
may help screen high-risk patients to select those
Hemodynamic Group A (n = 71) Group B (n = 10) Value of p
parameters
x ± SD Me Min-max x ± SD Me Min-max
EF (0) 53.7 ±15.3 55 20-78 33.3 ±5.2 33 25-45 0.0001
LVEDD (0) 52.7 ±9.9 48 42-72 66.4 ±4.0 68 59-72 0.0001
Vp (0) 43.1 ±4.3 45 34-48 39.7 ±4.4 39 33-47 0.023
n = 42 n = 10
EF (6) 55.5 ±13.6 57 23-78 37.6 ±8.3 36 25-50 0.0001
LVEDD (6) 50.4 ±8.1 47 42-72 61.0 ±5.9 61 55-69 0.0001
Vp (6) 43.9 ±3.7 45 34-48 41.3 ±3.9 41 33-47 0.046
n = 39 n = 7
EF (12) 55.1 ±13.6 57 25-78 39.1 ±8.6 37 29-55 0.001
LVEDD (12) 50.2 ±7.9 46 42-72 60.3 ±6.5 61 48-69 0.0001
Vp (12) 43.6 ±3.9 45 35-48 40.4 ±3.1 41 33-44 0.017
Hemodynamic Group A Group B
parameters
0 vs. 6 6 vs. 12 0 vs. 12 0 vs. 6 6 vs. 12 0 vs. 12
Value of p Value of p Value of p Value of p Value of p Value of p
EF 0.001 0.299 0.103 0.043 0.310 0.063
LVEDD < 0.001 0.715 0.002 0.043 0.465 0.046
Vp 0.001 0.082 0.128 0.068 0.345 0.726
Table I. Differences in hemodynamic parameters between patients with (group B) and without venous thrombosis
(group A) before (0) and at 6 and 12 months after pacemaker implantation
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who require early anticoagulation therapy. It is the
assessment of the dynamics of changes in certain
hemodynamic and biochemical parameters after
the pacemaker implantation procedure that makes
the paper original.
Venous stasis after vein ligation, increased blood
viscosity and endothelial injury (Virchow’s triad) in
the presence of endocavitary leads may trigger local
vascular wall inflammation and activate the coa g-
ulation system. This results in a release of the
inflammatory factors IL-6 and hsCRP, and coagula-
tion and fibrinolytic proteins, such as fibrinogen and
plasminogen activator inhibitor 1 (PAI-1). A clot nar-
rowing or occluding the vessel lumen is formed at
the injury site. Endogenous fibrinolysis and com-
plete clot lysis occur in less than 20% of the cases
[11-16]. Much more frequently (in about 50-70% of
the cases) clot dissolution is impaired and it grows
uncontrollably, obstructing the vessel [10, 17]. The
PAI-1 is also involved in the process.
The risk of developing thromboembolic complica-
tions remains constant regardless of the time elapsed
since implantation [5]. One out of two cases of throm-
bosis was reported at 1 year after implantation [18],
whereas superior vena cava syndrome developed 
at 6 years after implantation [19]. In a meta-analysis 
of 6256 patients with a pacemaker at a mean of 
6 months, angiography revealed subclavian or bra-
chiocephalic vein occlusion in 0.35% of the cases [20].
Right atrial thrombus around a pacing lead resulted
in cor pulmonale as late as 6 years after pacemaker
implantation and at 3.5 years after its removal and
leaving the fixed electrode in place [18]. In our group,
thrombosis developed at a mean of 13.06 months
after pacemaker implantation.
Epidemiological and clinical evidence shows the
relationship between biochemical markers of
endothelial injury and platelet activation and the
risk for developing VT [13], similar to our patient
groups. Pathological activation of coagulation and
attenuation of fibrinolysis lead to vein thrombosis
and obstruction, and may trigger pulmonary em -
bolism. In our study we confirmed the working
hypothesis that pacemaker patients with a history
of thrombotic events had higher levels of certain
prothrombotic and proinflammatory markers of
endothelial injury. It is noteworthy that their in -
creased levels in group B were much more frequent
prior to the thrombotic event and, in contrast to
group A, continued to rise during follow-up. Further-
more, these patients had heart failure, confirmed
by reduced left ventricular ejection fraction, increa -
sed diastolic dimensions and impaired filling. This
is not a novel relationship, because clinical evidence
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Figure 1. Mean value measurements (x) and standard
deviations (SD) of hemodynamic parameters in the
study groups
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shows elevated levels of coagulation factors and
an increased rate of thrombin generation in heart
failure patients [16, 17]. In order to assess the left
ventricular diastolic function a new parameter, early
mitral flow Vp, was used. It is insensitive to preload
changes and heart rate. Therefore, it seems to be
superior to the traditional diastolic function param-
eters, such as protodiastolic E wave/end-diastolic 
A wave ratio (E/A ratio), E wave deceleration time
(EDT) or isovolumetric relaxation time (IVRT). It also
helps to distinguish between nor mal and pseudo-
normal left ventricle filling pattern.
In our published and unpublished studies we
iden tified the following risk factors for venous
throm bosis following PM: a history of myocardial
infarction, temporary external pacing, arrhythmia,
venous anomalies, infection, NYHA class III and IV,
and smoking. In patients with more than 6 throm-
botic risk factors, combined with increased levels
of D-dimers, fibrinogen, tissue factor, VII, PAI-1 and
inflammatory factors such as IL-6 and hsCRP, the
likelihood of thrombosis is almost 100% [21].
It is not new, either, because of the well-known
effect of elevated fibrinogen on blood viscosity,
Biochemical Group A (n = 71) Group B (n = 10) Value of p
parameters
x ± SD Me Min-max x ± SD Me Min-max
D-dimers (0) 299.5 ±99 290 121-498 570.2 ±55.9 550.0 500-665 < 0.001
Fibrinogen (0) 3.6 ±0.8 3.5 1.8-5.6 6.1 ±1.0 5.65 4.9-7.7 < 0.001
TF (0) 213.7 ±54.7 190 160-440 390.8 ±43.1 389.0 320-460 < 0.001
VII (0) 90.7 ±16.6 90 60-129 116.2 ±8.4 120.0 100-126 < 0.001
PAI-1 (0) 11.7 ±4.7 11 5-23 21.1 ±1.9 22.0 18-23 < 0.001
IL-6 (0) 2.8 ±1.7 2.2 0.7-8.3 4.7 ±2.0 4.40 2.1-8.6 0.001
hsCRP (0) 2.1 ±1.2 2 0.5-5 4.9 ±0.7 5.0 4.0-6.0 < 0.001
n = 71 n = 10
D-dimers (7) 312.2 ±106.3 324 126-525 592.4 ±65.8 575.0 510-700 < 0.001
Fibrinogen (7) 3.6 ±0.8 3.5 1.8-5.6 6.6 ±0.8 6.74 5.6-7.9 < 0.001
TF (7) 226.1 ±70.9 200 160-459 425.8 ±37.5 430.0 360-470 < 0.001
VII (7) 91.4 ±17.0 90 60-130 132.8 ±8.7 132.0 120-145 < 0.001
PAI-1 (7) 13.1 ±5.3 12 6-26 25.3 ±1.9 25.50 22-28 < 0.001
IL-6 (7) 3.6 ±1.9 3.3 0.8-8.8 5.5 ±2.0 5.11 2.3-9.3 0.004
hsCRP (7) 3.2 ±1.8 3 1-8 9.9 ±2.1 9.5 8-14 < 0.001
n = 42 n = 10
D-dimers (6) 304.7 ±102.9 310 122-510 598.4 ±63.6 595 510-700 < 0.001
Fibrinogen (6) 3.3 ±0.7 3.3 1.8-5.5 6.7 ±0.9 6.75 5.6-8 < 0.001
TF (6) 218.8 ±68.1 192 151-445 429.8 ±38.3 435 360-480 < 0.001
VII (6) 85.7 ±13.5 82 62-130 132.8 ±8.7 132 120-145 < 0.001
PAI-1 (6) 11.5 ±4.8 10 5-26 25.8 ±1.8 25.5 23-29 < 0.001
IL-6 (6) 3.0 ±1.7 2.5 0.9-7.9 5.6 ±1.9 5.12 2.4-9.3 < 0.001
hsCRP (6) 2.5 ±1.5 2 1-8 10.7 ±3.2 9.5 8-17 < 0.001
n = 39 n = 7
D-dimers (12) 298.9 ±102.6 300 122-520 835.6 ±182.2 865 540-1136 < 0.001
Fibrinogen (12) 3.2 ±0.7 3 1.8-5.2 9.2 ±2.1 9.50 6-12 < 0.001
TF (12) 213.3 ±68 187 140-445 473.9 ±52.1 485 380-550 < 0.001
VII (12) 84.5 ±12.4 81 62-129 139.2 ±10.8 140 120-155 < 0.001
PAI-1 (12) 11.1 ±4.6 9 5-26 27.9 ±2.5 27.5 25-32 < 0.001
IL-6 (12) 2.8 ±1.5 2.2 0.9-7 8.4 ±2.7 8.17 5-13.5 < 0.001
hsCRP (12) 2.4 ±1.4 2 1-7 17.0 ±6.8 17 8-28 < 0.001
Table II. Differences in biochemical parameters between patients with (group B) and without venous thrombosis (group A)
before (0) and at 7 days, 6 and 12 months after pacemaker implantation
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platelet aggregation and atherothrombotic vascu-
lar lesions. Tissue factor plays the main role in the
extrinsic pathway as the cellular receptor for plasma
factor VII, whereas low levels of D-dimers exclude
venous thrombosis with high probability. Like Kor -
keila et al. [22], we noticed that patients who ini-
tially had elevated levels of thrombotic and inflam-
matory factors, and who had higher central venous
pressure due to heart failure, easily activate throm-
bosis, which may be initiated by the endothelial
injury during the pacemaker lead introduction. The
above-mentioned thrombosis risk factors play an
important role in this process. Altogether it may
lead to vein occlusion. 
In the present study univariate analysis (OR) and
the area under the ROC curve (AUC) identified D-di -
mers, fibrinogen and tissue factor as the strongest
factors predisposing to thrombotic complications. 
It is noteworthy that the patients had not been
receiving anticoagulants that might influence le v-
els of the markers, until the event occurred. Anti-
coagulation as a prophylactic measure following
PM, especially in group B, requires further clarifi-
cation in prospective studies. It seems that it might
play a crucial role in the process.
The present findings confirm that the inflamma-
tory markers and coagulation factors increase with
pacemaker implantation and rise further in patients
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Figure 3. Mean value measurements (x) and standard deviations (SD) of proinflammatory markers in the study groups
x ± SD Group A x ± SD Group B
0                7 days          6 months       12 months 0                7 days          6 months       12 months
Parameters AUC ± 95% (CI) Value of p Cut-off Sensitivity Specificity
LVEDD [mm] 0.853 0.757-0.922 < 0.0001 > 58 100 71.8
EF [%] 0.865 0.772-0.931 < 0.0001 ≤ 35 90 83.1
D-dimers [ng/ml] 1.000 0.955-1.000 < 0.0001 > 498 100 100
Fibrinogen [mg/ml] 0.987 0.933-1.000 < 0.0001 > 4.7 100 88.7
TF [ng/ml] 0.976 0.915-0.997 < 0.0001 > 300 100 94.4
VII [%] 0.901 0.815-0.957 < 0.0001 > 99 100 67.6
PAI-1 [ng/ml] 0.942 0.866-0.982 < 0.0001 > 17 100 85.9
IL-6 [pg/ml] 0.778 0.672-0.863 0.0001 > 2.45 90 60.6
hsCRP [µg/ml] 0.967 0.901-0.994 < 0.0001 > 3 100 81.7
Table III. Area under the ROC curve (AUC) and cut-off points for hemodynamic and biochemical parameters before
pacemaker implantation
Parameters Value of p Odds ratio (OR) ± 95% (CI)
LVEDD [mm] 0.003 1.183 1.059-1.321
EF [%] 0.003 0.895 0.833-0.962
D-dimers [ng/ml] 0.001 590.5 40.203-24 760
Fibrinogen [mg/ml] 0.022 227.5 2.225-22 848
TF [ng/ml] 0.001 189.8 15.42-7280
VII [%] 0.002 1.145 1.05-1.248
PAI-1 [ng/ml] 0.001 1.674 1.231-2.278
IL-6 [pg/ml] 0.006 1.703 1.168-2.484
hsCRP [µg/ml] 0.005 26.64 2.77-257
Table IV. Logistic regression analysis of hemodynamic and biochemical parameters before pacemaker implantation
Time Time
at risk of subsequent venous thrombosis. Patients
in group B had worse systolic (lower EF) and dias-
tolic (lower Vp and higher left ventricular diameter)
left ventricular function and were characterized by
a more pronounced inflammatory and prothrom-
botic status than those in group A. The highest risk
for venous thrombosis incidence was correlated
with D-dimers, fibrinogen and tissue factor. The
potential relation between these markers and heart
failure also seems important. These biochemical
markers and hemodynamic factors can be used
(together) as screening (selecting patients at high
risk) criteria in a future meta-analysis. 
Due to the small sample size and relatively short
follow-up, multivariate analysis of interactions be -
tween various markers of thrombotic risk and pa -
1034 Arch Med Sci 6, December / 2012
tients’ past medical history could not be perfor med.
It would also be interesting to analyze genetic factors
predisposing to VT and such a study is un derway.
In conclusion, patients with venous thrombosis
after pacemaker implantation had increased levels
of laboratory prothrombotic and proinflammatory
markers prior to implantation, which continued to
rise at follow-up. Levels of D-dimers, fibrinogen and
tissue factor were the most powerful biochemical
predictors of venous thrombosis.
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